Objective: This study was designed to establish prognostic factors for survival of patients with locally advanced or metastatic urothelial cancer. We have furthermore investigated changes in patient characteristics and treatment strategies during the last 20 years. Patients and Methods: Between 1992 and 1997, a total of 156 patients with newly diagnosed recurrent locally advanced disease (nonresectable, radioresistant) and/or metastatic transitional cell carcinoma of the urothelial tract were included in a protocol evaluating clinical and laborattory prognostic factors at baseline. The relationship between these characteristics and survival was analyzed using univariate and multivariate methods. The results were compared to the survival results of similar patients treated previously from 1976 to 1991. Results: Median survival after diagnosis of recurrent locally advanced or metastatic disease was 5.8 months. Multivariate analysis showed that good performance status (PS), normal alkaline phosphatase (AP), absence of liver metastases and chemotherapy were independent prognostic factors for long survival. An increase in survival was found when comparison was made with 240 patients treated in the period from 1976 to 1991, but the period of treatment had no independent importance in multivariate analysis. Conclusion: PS, AP and liver metastases are the major important prognostic factors in metastatic urothelial cancer. Stage migration and increased use of chemotherapy may have contributed to improved median survival during the last 20 years.

Keywords:
Prognostic factors, Bladder cancer, Chemotherapy, Stage migration
1.
Bentzen SM: Towards evidence–based radiation oncology: Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol 1998;46:5–18.
2.
Geller NL, Sternberg CN, Penenberg D, Scher HI, Yagoda A: Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy. Cancer 1991;67:1525–1531.
3.
Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG: Long–term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173–3181.
4.
Fosså SD, Sternberg C, Scher HI, Theodore CH, Mead B, Dearnaley D, Roberts JT, Skovlund E: Survival of patients with advanced urothelial cancer treated with cisplatin–based chemotherapy. Br J Cancer 1996;74: 1655–1659.
5.
Hillcoat BL, Raghavan D, Matthews J, Kefford K, Yuen K, Woods R, Olver I, Bishop J, Pearson BS, Coorey G, Levi J, Abbott RL, Aroney R, Gill PG, McLennan R: A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 1989;7:706–709.
6.
Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler JP, Tannock IF, Raghavan D, Stuart–Harris R, Sarosdy MF, Lowe BA, Blumenstein B, Trump D: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. J Clin Oncol 1992;10:1066–1073.
7.
Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050–1055.
8.
Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJS, Trump D: Long–term follow–up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997;15:2564–2569.
9.
Sengeløv L, Nielsen OS, Kamby C, von der Maase H: Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract rumors. A phase II trial with evaluation of prognostic factors. Cancer 1995; 76:1797–1803.
10.
Soloway MS, Einstein AB, Corder MP, Bonney W, Prout GR, Coombs J: A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A study. Cancer 1983;52:767–771.
11.
Troner M, Birch R, Omura GA, Williams S: Phase III comparison of cisplatin alone versus ciplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: A Southeastern Cancer Study Group trial. J Urol 1987;137:660–662.
12.
Sengeløv L, Kamby C, Schou G, von der Maase H: Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 1994;74:123–133.
13.
van der Gaast A, Verweij J, Planting AST, Hop WCJ, Stoter G: Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995;13:1720–1725.
14.
Sengeløv L, Kamby C, von der Maase H: Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol 1996;155:111–114.
15.
WHO Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979, p 48.
16.
Dombernowsky P, Worm AM, Hainau B, Hansen HH, Nissen NI: The Radner needle, a bone–marrow biopsy device. Scand J Haematol 1974;12:270–273.
17.
Sengeløv L, von der Maase H, Kamby C, Jensen LI, Rasmussen F, Horn T, Nielsen SL, Steven K: Assessment of patients with metastatic transitional cell carcinoma of the urinary tract. J Urol 1999;162:343–346.
18.
Bergkvist A: Classification of bladder tumours based on the cellular pattern, preliminary report of a clinical–pathological study of 300 cases with a minimum follow–up of eight years. Acta Chir Scand 1965;130:371–378.
19.
Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
20.
Cox DR: Regression models and life tables. JR Statist Soc B 1972;34:187–220.
21.
Andersen LJ, Sengeløv L, Kamby C, von der Maase H: Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer. Acta Oncol 1998;37:110– 112.
22.
Geertsen PF, Sengeløv L, Larsen SK, von der Maase H: A phse II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium. Eur J Cancer 1993;29A:347–350.
23.
Sengeløv L, Kamby C, Lund B, Engelholm SA: Docetaxel (taxotere) and cisplatin in metastatic urothelial cancer: A phase II study. J Clin Oncol 1998;16:3392–3397.
24.
Von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 1999;10:1461–1465.
25.
Babaian RJ, Johnson DE, Llamas L, Ayala AG: Metastases from transitional cell carcinoma of the urinary bladder. Urology 1980;16:142– 144.
26.
Roth BJ: Chemotherapy for advanced bladder cancer. Semin Oncol 1996;23:633–644.
27.
Steinberg GD, Trump D, Cummings KB: Metastatic bladder cancer. Urol Clin North Am 1992;19:735–746.
28.
Igawa M, Ohkuchi T, Ueda M, Usui T, Kawanishi M: Analyses of factors affecting the outcome of combination chemotherapy in patients with advanced bladder cancer. Eur Urol 1991; 20:12–15.
29.
Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604–1608.
30.
Wishnow KI, Tenney DM: Will Rogers and the results of radical cystectomy for invasive bladder cancer. Urol Clin North Am 1991;18:529– 537.
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.